Search results
Results from the WOW.Com Content Network
Lenalidomide, sold under the brand name Revlimid among others, is a medication used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes (MDS). [8] For multiple myeloma, it is a first line treatment, and is given with dexamethasone . [ 8 ]
The objective of the study was to determine if the addition of elotuzumab with lenalidomide and dexamethasone would increase progression-free survival in patients with refractory multiple myeloma. [10] [11] This randomized, open-label, phase 3, multicenter trial studied patients 18 years and older with multiple myeloma and measurable disease. [10]
Multiple myeloma is the second-most prevalent blood cancer (10%) after non-Hodgkin's lymphoma. [154] It represents about 1.8% of all new cancers and 2.1% of all cancer deaths. [7] Multiple myeloma affects slightly more men than women.
Celgene Provides REVLIMID ® Regulatory Update REVLIMID Granted Approval for Treatment of Patients with Relapsed or Refractory Multiple Myeloma in China REVLIMID ...
Oral Anti-Cancer Therapy REVLIMID ® (lenalidomide) Now Indicated as a Treatment for Patients with Rare Form of Blood Disease Treatment indicated for patients with transfusion-dependent anaemia ...
For premium support please call: 800-290-4726 more ways to reach us
In pharmacokinetics, a maintenance dose is the maintenance rate [mg/h] of drug administration equal to the rate of elimination at steady state. This is not to be confused with dose regimen , which is a type of drug therapy in which the dose [mg] of a drug is given at a regular dosing interval on a repetitive basis.
For premium support please call: 800-290-4726 more ways to reach us